Google and Japan’s Chiral Share the Stage to Co-Envision the Next Decade of Biopharma TherapiAI, a pioneering biotech AI startup, hosted the “AI-Driven Future of Biopharma: From R&D Innovation to Digital Twin” seminar today (7th) at the Taipei Bioinnovation Park.
Continue Reading
Leading AI pharmaceutical brand TherapiAI is expanding its footprint in Asia! Following a successful entry into the Japanese market, TherapiAI officially launched its strategic expansion into Southeast Asia today (the 24th). The company recently made its regional debut by unveiling
Continue Reading
The Investment Dilemma: The “Must-Play” Game of the Era. AI has emerged as the defining strategic priority and a primary target for capital allocation across industries. From pharmaceuticals to retail, companies are aggressively deploying Generative AI and automation at a
Continue Reading
Antibody-Drug Conjugates (ADCs) are among the most promising precision therapies today. By combining the high targeting capability of monoclonal antibodies with the potent cytotoxicity of small-molecule drugs, they have become a new focal point in the R&D of cancer and
Continue Reading
ADC Opportunities and Challenges: High Technical Barriers are the Cornerstone of Long-Term CDMO Advantage. For pharmaceutical CDMOs, ADCs present immense commercial opportunities. On one hand, the rapid expansion of global clinical pipelines is driving outsourcing demand. On the other hand,
Continue Reading
therapiAI, a leading AI pharmaceutical company, announced today the launch of the world’s first AI Agent dedicated to Antibody-Drug Conjugates (ADCs). This technology significantly compresses the traditional 2-3 year R&D exploration phase. By following the AI Agent’s recommendations, researchers can
Continue Reading
Article Categories
Article Categories
Article Categories
Latest Articles
Follow Us
